Should cT2 esophageal cancer get neoadjuvant treatment before surgery?

od Thuss-Patience, Peter, Vecchione, Loredana, Keilholz, Ulrich
Izdano u J Thorac Dis (2017)

Importance of genetic screens in precision oncology

od Mulero-Sánchez, Antonio, Pogacar, Ziva, Vecchione, Loredana
Izdano u ESMO Open (2019)

Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature

od Liebs, Sandra, Nonnenmacher, Anika, Klauschen, Frederick, Keilholz, Ulrich, Vecchione, Loredana
Izdano u ESMO Open (2019)

ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer

od Vecchione, Loredana, Stintzing, Sebastian, Pentheroudakis, George, Douillard, Jean-Yves, Lordick, Florian
Izdano u ESMO Open (2020)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

od Geva, Ravit, Vecchione, Loredana, Tejpar, Sabine, Piessevaux, Hubert, Van Cutsem, Eric, Prenen, Hans
Izdano 2013

Immunotherapy in Gastrointestinal Cancers

od Procaccio, Letizia, Schirripa, Marta, Fassan, Matteo, Vecchione, Loredana, Bergamo, Francesca, Prete, Alessandra Anna, Intini, Rossana, Manai, Chiara, Dadduzio, Vincenzo, Boscolo, Alice, Zagonel, Vittorina, Lonardi, Sara
Izdano u Biomed Res Int (2017)

Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma

od Andolfo, Immacolata, Petrosino, Giuseppe, Vecchione, Loredana, De Antonellis, Pasqualino, Capasso, Mario, Montanaro, Donatella, Gemei, Marica, Troncone, Giancarlo, Iolascon, Achille, Orditura, Michele, Ciardiello, Fortunato, De Vita, Fernando, Zollo, Massimo
Izdano 2011

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling

od Asbagh, Layka Abbasi, Vazquez, Iria, Vecchione, Loredana, Budinska, Eva, De Vriendt, Veerle, Baietti, Maria Francesca, Steklov, Mikhail, Jacobs, Bart, Hoe, Nicholas, Singh, Sharat, Imjeti, Naga-Sailaja, Zimmermann, Pascale, Sablina, Anna, Tejpar, Sabine
Izdano u Oncotarget (2014)

Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAF(V600E) Colorectal Cancer

od Coffee, Erin M., Faber, Anthony C., Roper, Jatin, Sinnamon, Mark J., Goel, Gautam, Keung, Lily, Wang, Wei Vivian, Vecchione, Loredana, de Vriendt, Veerle, Weinstein, Barbara J., Bronson, Roderick T., Tejpar, Sabine, Xavier, Ramnik J., Engelman, Jeffrey A., Martin, Eric S., Hung, Kenneth E.
Izdano 2013

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

od Scherr, Anna-Lena, Mock, Andreas, Gdynia, Georg, Schmitt, Nathalie, Heilig, Christoph E., Korell, Felix, Rhadakrishnan, Praveen, Hoffmeister, Paula, Metzeler, Klaus H., Schulze-Osthoff, Klaus, Illert, Anna L., Boerries, Melanie, Trojan, Jörg, Waidmann, Oliver, Falkenhorst, Johanna, Siveke, Jens, Jost, Philipp J., Bitzer, Michael, Malek, Nisar P., Vecchione, Loredana, Jelas, Ivan, Brors, Benedikt, Glimm, Hanno, Stenzinger, Albrecht, Grekova, Svetlana P., Gehrig, Tobias, Schulze-Bergkamen, Henning, Jäger, Dirk, Schirmacher, Peter, Heikenwalder, Mathias, Goeppert, Benjamin, Schneider, Martin, Fröhling, Stefan, Köhler, Bruno C.
Izdano u Cell Death Dis (2020)